MAIA Biotechnology Inc
For the period ended Dec 31, 2023. Filed Mar 21, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 21, 2024
MAIA$1.09+2.8%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations
| Years Ended December 31, | ||
|---|---|---|
| 2023 | 2022 | |
| Operating expenses: | ||
| Research and development expenses | $11,112,257 | $8,933,314 |
| General and administrative expenses | 9,070,124 | 6,143,527 |
| Ratchet share expense | — | 1,099,360 |
| Total operating expenses | 20,182,381 | 16,176,201 |
| Loss from operations | (20,182,381) | (16,176,201) |
| Other income (expense): | ||
| Interest expense | (6,863) | (6,967) |
| Interest income | 34,490 | 1,870 |
| Australian research and development incentives | 176,719 | 313,625 |
| Change in fair value of warrant liability | 205,130 | 98,394 |
| Other income (expense) net: | 409,476 | 406,922 |
| Net loss | (19,772,905) | (15,769,279) |
| Deemed dividend on warrant modification | — | (450,578) |
| Net loss attributable to MAIA Biotechnology, Inc. shareholders | $(19,772,905) | $(16,219,857) |
| Net loss per share | ||
| Basic and diluted | $(1.49) | $(1.75) |
| Weighted average common shares outstanding basic and diluted | 13,261,572 | 9,276,761 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.